Corcept Therapeutics IncorporatedCORT
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United States · corcept.com
Discovers and develops drugs that modulate the effects of the hormone cortisol; markets Korlym for hypercortisolism and develops selective cortisol modulators such as relacorilant.
Key ratios
Operating cash flow growth
-39.9%TTM
2025
-28.4%2024
56.5%2023
5.3%
EPS growth
-59.3%TTM
2025
-33.3%2024
30.9%2023
8.1%
FCF / Sales
18.6%2025
2024
29.1%2023
26.2%
Net margin
6.6%TTM
2025
13.1%2024
20.9%2023
22.0%
ROA
0.5%TTM
2025
3.3%2024
11.7%2023
11.1%
ROE
8.2%TTM
2025
15.0%2024
23.8%2023
21.1%
Revenue growth
16.0%TTM
2025
12.8%2024
39.9%2023
20.0%
Track CORT in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer